The global CAR-T Cell therapy market is anticipated to grow over 20 percent CAGR during the forecasting period and likely to touch nearly US$ 8 Billion landmarks in 2028. The year 2017 was the milestone year for the CAR-T therapy as US FDA has approved two CAR-T cell therapies Kymriah in August 2017 and Yescarta in October 2017. In July 2020, US FDA has approved 3rd CAR-cell therapy Tecartus for the treatment of relapsed or refractory mantle cell lymphoma (MCL). To date, it is the only approved therapy for the treatment of MCL across the world.
In the context of antigens, CD-19, CD-20 and CD22 are considered potential targets by healthcare companies and research organizations. Antigen CD-19 holds the majority of the share in CAR-T clinical trials. All three approved Kymriah, Yescarta and Tecartus CAR-T cell therapy is based on antigen CD-19. At present total of 164 CAR-T studies are enrolled in the United States National Library of Medicine for the CD19 antigen across the various parts of the world. The United States and China hold the majority share of these studies in 2020.
MNG Tracker report titled “Global CAR-T Cell Therapy Market by Application (Acute Lymphoblastic Leukaemia (ALL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)), by Regions (North America, Europe, Asia Pacific, Latin America Middle East, Africa), by Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvIII, Others) Market Products (Yescarta, Kymriah)” provides an all-encompassing insight of Chimeric Antigen Receptor (CAR-T) cell therapy industry.
The objective of this studyis to analyze Global CAR-T Cell Therapy market by two prospective - CAR-T cell therapy market and pharmaceutical company’s initiatives. Under the market section, we identifying the market growth potentials and market value by CAR-T cell therapy applications, antigens, regions and marketed products, rules & regulations, reimbursements policy in various countries, approved and marketed therapy, growth drivers, challenges; whereas in company section our objectives are: to find out the key companies latest initiatives, company CAR-T clinical trials, product candidate/pipeline in this market place.
This 257 pages study report with 46 Figures & 5 Tables studies the Global CAR-T Cell Therapy market from 11 view points:
Market and Forecast
Market Share and Forecast
By Therapeutic Applications CAR-T Cell Therapy - Market & Forecast
By Antigens CAR-T Cell Therapy - Market & Forecast
By Regions CAR-T Cell Therapy - Market & Forecast
By Marketed Products CAR-T Cell Therapy - Market & Forecast
CAR-T Cell Therapy Product Approvals by Regulatory Body Globally
MNG Tracker is a market research company which offer market research reports and database subscription service. Continuous tracking on latest changes in the industry and predict about the emerging needs, challenges and opportunities, is the essential needs for the growth of the business. MNG Tracker is exists for that. MNG Tracker is steadily monitored on the latest happening in the industries, companies and regulatory policies around the world. MNG Tracker is all about market, research and data. We know our clients; who they are, what they see and what they do. MNG Tracker team is fully dedicated to achieve their needs and expectation.